Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P41271
UPID:
NBL1_HUMAN
Alternative names:
DAN domain family member 1; Protein N03; Zinc finger protein DAN
Alternative UPACC:
P41271; A3KFI7; Q5TGZ2; Q5U0N4; Q96L68
Background:
Neuroblastoma suppressor of tumorigenicity 1, also known as DAN domain family member 1, Protein N03, and Zinc finger protein DAN, is identified with the UniProt accession number P41271. It is posited as a potential tumor suppressor gene specifically for neuroblastoma. Its role is crucial in halting the cellular transformation process by preventing cells from progressing through the G1/S final stage.
Therapeutic significance:
Understanding the role of Neuroblastoma suppressor of tumorigenicity 1 could open doors to potential therapeutic strategies.